Clinical trials: Lenalidomide, open to volunteers
Multiple Myeloma, Triple Negative Breast Cancer
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose…
- Conditions
- Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
- Trial name
- NCT07341867
- Testing
- Dexamethasone, Bortezomib, LENALIDOMIDE
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Andrew Hantel, MD
Marginal Zone Lymphoma
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and…
- Trial name
- MOTIVE (NCT06534463)
- Testing
- All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Follicular Lymphoma
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in…
- Trial name
- NCT05846763
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
Lenalidomide is a standard of care for maintenance therapy after autologous stem cell transplantation in newly diagnosed myeloma patients.
- Trial name
- IFM 2024_06 (NCT06931704)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 36 sites in France
- Volunteers
- 176 people
- Sponsor
- Nantes University Hospital
Follicular Lymphomas
ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma
Primary Objective: To compare the complete response rate (CR rate) after induction treatment between the ZR2 regimen and the R2 regimen.<br/><br/>Secondary Objectives: To compare the objective response rate (ORR) after induction…
- Trial name
- NCT07505849
- Testing
- Zanubrutinib+R2, R2
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- KeshuZhou
Diffuse Large B-Cell Lymphoma
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.
- Trial name
- NCT06665217
- Testing
- Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy
- Volunteers
- 80 people
- Sponsor
- Navy General Hospital, Beijing
Follicular Lymphoma
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
This study is planned to prospectively evaluates the efficacy and safety of the zanubrutinib, obinutuzumab, and lenalidomide (ZGR) combination regimen in treatment-naïve follicular lymphoma (FL) patients in a Chinese population.
- Trial name
- ZGR in TN FL (NCT07299149)
- Testing
- Induction Therapy: Zanubrutinib, obinutuzumab, lenalidomide, Maintenance therapy: Zanubrutinib, lenalidomide
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop).
- Trial name
- NCT06182774
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- 31 sites in Canada
- Volunteers
- 570 people
- Sponsor
- Canadian Cancer Trials Group
Follicular Lymphoma, Marginal Zone Lymphoma
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma
- Trial name
- NCT04792502
- Testing
- Mosunetuzumab, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Brown University
HIV (Human Immunodeficiency Virus), HIV -1 Infection
Combining Latency Reversing Agents to Address the HIV Reservoir
The PLUTO trial aims to contribute to the worldwide search for a functional cure of HIV. One the strategies ("shock and kill' strategy) aims to reverse the HIV-reservoir from latency by increasing cell-associated HIV-RNA, which…
- Trial name
- PLUTO (NCT07384624)
- Testing
- Pyrimethamine (PYR), Lenalidomide, Topiramate (drug)
- Where
- 4 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- Erasmus Medical Center
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a…
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Trial name
- NCT06015880
- Testing
- Biospecimen Collection, Computed Tomography, Lenalidomide
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Newly Diagnosed Multiple Myeloma (NDMM)
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple…
- Trial name
- NCT07891923
- Testing
- Daratumumab (Intravenously) with VRd (Bortezomib, Lenalidomide, and Dexamethasone)
- Where
- 2 sites in India
- Volunteers
- 52 people
- Sponsor
- Tata Memorial Centre
DLBCL
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
This is a A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT05552937
- Testing
- Tafasitamab and Lenalidomide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
IgG4 Related Disease
A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
For patients with active proliferative IgG4-RD, we plan to conduct a 52-week prospective randomized controlled trial to compare the efficacy and safety of 5mg lenalidomide plus prednisone, 10mg lenalidomide plus prednisone, and…
- Trial name
- IgG4-RD (NCT07068165)
- Testing
- 5mg lenalidomide, 10mg lenalidomide, Prednisone monotherapy
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Peking Union Medical College Hospital
Multiple Myeloma
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that…
- Trial name
- NCT04025450
- Testing
- Chidamide+VRD, VRD
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma Refractory
Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
The goal of this clinical trial is to learn if the antibody drug HuL001, combined with Lenalidomide/Dexamethasone works to treat Multiple Myeloma patients.
- Trial name
- NCT07210047
- Testing
- HuL001, Lenalidomide/Dexamethasone
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- HuniLife Biotechnology, Inc.
Plasma Cell Leukemia
Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation
Single-Arm phase 2 trial evaluating efficacy of incorporating Daratumumab to treatment of newly diagnosed primary plasma cell leukemia.
- Trial name
- PCL-2 (NCT05054478)
- Testing
- Daratumumab
- Volunteers
- 29 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma, Cancer
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM).
- Trial name
- NCT05145400
- Testing
- Isatuximab, Lenalidomide, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
DLBCL - Diffuse Large B Cell Lymphoma
Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient…
- Trial name
- NCT06299553
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Incyte Biosciences Italy S.r.l
Primary CNS Lymphoma
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
After standard treatment of primary central nervous system lymphoma (PCNSL), high-dose methotrexate induction therapy, and consolidation therapy, most patients reach complete remission, but within the first 6 months, 35-60% of…
- Trial name
- Lemon-C (NCT04627753)
- Testing
- Rituximab, lenalidomide
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim, Seok Jin